Scopolamine prevents dreams during general anesthesia

Area of Science:

• Anesthesiology
• Neuroscience
• Pharmacology

Background:

• Dreaming during anesthesia remains poorly understood.
• The efficacy of anticholinergic drugs in preventing anesthesia-related dreams is not well-established.
• Anticholinergic premedication is commonly used in anesthesia.

Purpose of the Study:

• To evaluate the effectiveness of intramuscular atropine and scopolamine in preventing dreams during general anesthesia.
• To assess the impact of these anticholinergic drugs on dream incidence and recall post-anesthesia.
• To investigate the role of the central cholinergic system in anesthesia-induced dreams.

Main Methods:

• Healthy women undergoing minor gynecologic surgery were randomized into two groups.
• One group received intramuscular scopolamine (2.5 microg/kg), the other atropine (10 microg/kg).
• Anesthesia was induced and maintained with propofol and nitrous oxide; dream activity was assessed via interviews at 20 minutes and 6 hours post-surgery.

Main Results:

• None of the patients receiving scopolamine reported dreams at 20 minutes post-recovery, compared to 47% in the atropine group.
• Dream recall remained low in the scopolamine group (6%) at 6 hours, while it was 43% in the atropine group.
• No significant differences in sedation levels or anesthetic requirements were observed between the groups.

Conclusions:

• Intramuscular scopolamine appears to prevent dreams or dream recall in healthy young women.
• The findings support the hypothesis that drugs acting on the central cholinergic system affect dreaming.
• Scopolamine may be a viable option for reducing dream incidence in specific surgical and anesthetic contexts.